Clinical trials: Dementia Alzheimers
COVID-19
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5…
- Trial name
- NCT04916886
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
- Where
- China
- Volunteers
- 2,021 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Alzheimer's Disease, Brain Neoplasm
PET Scan of Brain Metabolism in Relation to Age and Disease
The main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients.
- Conditions
- Alzheimer's Disease, Brain Neoplasm, Niemann Pick Disease
- Trial name
- NCT00001972
- Testing
- 15 O Water
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
As the population increases and aging intensifies, cognitive disorders represented by Alzheimer's disease (AD) not only pose a severe threat to public health but also bring significant social and economic burdens.
- Trial name
- NCT06741553
- Testing
- Lecanemab 10 mg/kg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alzheimer's Disease
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.
- Trial name
- NCT01734395
- Testing
- Galantamine
- Volunteers
- 1,882 people
- Sponsor
- Janssen Korea, Ltd., Korea
Gut Microbiota, Mild Cognitive Impairment
Intervention of Intestinal Microorganism in Mild Cognitive Impairment
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective drugs targeting this disease.
- Conditions
- Gut Microbiota, Mild Cognitive Impairment, Dementia, Alzheimer Type, Neuroimaging
- Trial name
- NCT03991195
- Testing
- Probiotic supplemented intervention
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XuanwuH 2
Caregiver Burden
Building a Bridge (BAB) Between Clinical and Community Care
Dementia diagnosis triggers a transitional phase for the individuals and their families, often causing emotional distress and family conflicts due to the ambiguity of the illness and future trajectories.
- Trial name
- BAB (NCT03932812)
- Testing
- Options Counselor Health Educator (OC-HE) Intervention
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Sato Ashida
Alzheimers Disease, Dementia
University of Central Florida Music Study
The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes.
- Conditions
- Alzheimers Disease, Dementia, Dementia Alzheimer Type
- Trial name
- NCT07306065
- Testing
- Music intervention
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Alzheimer Disease, Parkinson Disease
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients
This double-blind, randomized, placebo-controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in AD and PD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine…
- Trial name
- NCT04044131
- Testing
- Metabolic Cofactor Supplementation, Sorbitol
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul Medipol University Hospital
Mild Cognitive Impairment
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
This is a single center imaging study that will recruit 60 participants who are enrolled in the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy for Amyloid Transformation in AD (BEAT-AD)…
- Trial name
- AcAc PET (NCT03130036)
- Testing
- [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer's Disease
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-388 and MNI 390, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed…
- Trial name
- NCT00886951
- Testing
- I123MNI388/I123MNI390
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES), Suspected Alzheimer's Disease (AD)
FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD
The primary objective of this study is to demonstrate the safety and efficacy of positron emission tomography (PET) imaging with a radioactive compound called [F-18]FDDNP in subjects with suspected Alzheimer's disease or…
- Trial name
- FDDNP (NCT04311281)
- Testing
- [F-18]FDDNP-PET
- Sponsor
- University of California, Los Angeles
Alzheimer Disease, Mild Cognitive Impairment
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders
- Trial name
- NCT05364307
- Testing
- Prescreener database
- Where
- 19 sites in United States, Canada
- Volunteers
- 1,555 people
- Sponsor
- Global Alzheimer's Platform Foundation
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01690195
- Testing
- ABT-126
- Where
- 39 sites in United States, Canada and 5 more
- Volunteers
- 343 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer Dementia, Late Onset Alzheimer Disease
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- REGEN-BRAIN© (NCT04838301)
- Testing
- Allopregnanolone
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Arizona
Alzheimer's Disease, Dementias
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
To establish a cutoff value using a ratio of CSF tau to Aβ42 (tau/Aβ42) for distinguishing patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects.
- Trial name
- NCT01730430
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Alzheimer Disease, Battery
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs.
- Trial name
- WP3_P002 (NCT02288000)
- Testing
- Memantine
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer Disease
Correlation of P-glycoprotein Polymorphisms With Microbial Metabolites in Patients With Alzheimer's Disease on Medication
The importance of the proposed study concerns the understanding of the way in which each drug acts in each organism separately, both at the genome level and at the microbiome level.
- Trial name
- NCT05532644
- Testing
- AD drugs
- Where
- Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Alzheimer Disease and Related Dementias
Designing Care Management for Hospice Transitions for Persons Living With Advanced Dementia
This study will test a care management intervention to guide end-of-life care and hospice transitions for persons with dementia and their care partners receiving home healthcare and ascertain feasibility, acceptability, fidelity…
- Trial name
- ENGAGE-D (NCT07182357)
- Testing
- Dementia Care Management Checklist for Hospice Transitions
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- New York University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.